Scribe Therapeutics, Inc. 8-K

What Happened Scribe Therapeutics, Inc. (SCTX) announced on July 27, 2026 that it filed an Amended and Restated Certificate of Incorporation (the “Charter”) with the Delaware Secretary of State and implemented Amended and Restated Bylaws in connection with the closing of its initial public offering. The changes had been approved by the company’s board and stockholders and were made effective immediately prior to the Offering’s closing, as described in the company’s final prospectus dated July 23, 2026 (Form S-1, File No. 333-297246).

Key Details

• Filing date: July 27, 2026; Prospectus date: July 23, 2026.
• Documents: Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws (filed as Exhibits 3.1 and 3.2).
• Purpose/effect: Amendments became effective immediately prior to the closing of the company’s IPO.
• Capital detail noted: common stock par value is $0.001 per share (as referenced in the Prospectus).

Why It Matters These amended governance documents define the company’s capital structure and corporate governance terms that apply to new public shareholders following the IPO. Investors should review the Charter and Bylaws (and the “Description of Capital Stock” section of the Prospectus) to understand shareholder rights, board procedures, and any provisions that could affect voting, transfer restrictions, or other corporate actions. The 8-K confirms the governance framework now in effect for Scribe as a public company.